Celgene Goes After Synthon's Skin Cancer Drug Generic
Synthon Pharmaceuticals Inc. and Alvogen Pine Brook LLC are infringing four of Celgene Corp.'s patents by seeking approval for a generic version of the blockbuster skin cancer medication Pomalyst, the branded...To view the full article, register now.
Already a subscriber? Click here to view full article